EP Patent

EP3569234A1 — Morphinan derivatives for the treatment of drug overdose

Assigned to Alkermes Pharma Ireland Ltd · Expires 2019-11-20 · 6y expired

What this patent protects

The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:

USPTO Abstract

The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:

Drugs covered by this patent

Patent Metadata

Patent number
EP3569234A1
Jurisdiction
EP
Classification
—
Expires
2019-11-20
Drug substance claim
No
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.